These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 12170384

  • 1. HSV1716 persistence in primary human glioma cells in vitro.
    Harland J, Papanastassiou V, Brown SM.
    Gene Ther; 2002 Sep; 9(17):1194-8. PubMed ID: 12170384
    [Abstract] [Full Text] [Related]

  • 2. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.
    Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M, Hadley D, Patterson J, Brown SM, Rampling R.
    Gene Ther; 2004 Nov; 11(22):1648-58. PubMed ID: 15334111
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
    Mace AT, Harrow SJ, Ganly I, Brown SM.
    Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
    [Abstract] [Full Text] [Related]

  • 6. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma.
    MacKie RM, Stewart B, Brown SM.
    Lancet; 2001 Feb 17; 357(9255):525-6. PubMed ID: 11229673
    [Abstract] [Full Text] [Related]

  • 7. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.
    Friedman A, Tian JP, Fulci G, Chiocca EA, Wang J.
    Cancer Res; 2006 Feb 15; 66(4):2314-9. PubMed ID: 16489036
    [Abstract] [Full Text] [Related]

  • 8. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
    Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN, Chiocca EA.
    J Virol; 2000 May 15; 74(10):4765-75. PubMed ID: 10775615
    [Abstract] [Full Text] [Related]

  • 9. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
    Kambara H, Okano H, Chiocca EA, Saeki Y.
    Cancer Res; 2005 Apr 01; 65(7):2832-9. PubMed ID: 15805284
    [Abstract] [Full Text] [Related]

  • 10. [Gene therapy for brain tumors using herpes simplex virus vector].
    Toda M.
    Nihon Rinsho; 2005 Sep 01; 63 Suppl 9():510-4. PubMed ID: 16201573
    [No Abstract] [Full Text] [Related]

  • 11. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
    Quigg M, Mairs RJ, Brown SM, Harland J, Dunn P, Rampling R, Livingstone A, Wilson L, Boyd M.
    Med Chem; 2005 Sep 01; 1(5):423-9. PubMed ID: 16787326
    [Abstract] [Full Text] [Related]

  • 12. Herpes simplex virus type 1 strain HSV1716 grown in baby hamster kidney cells has altered tropism for nonpermissive Chinese hamster ovary cells compared to HSV1716 grown in vero cells.
    Conner J, Rixon FJ, Brown SM.
    J Virol; 2005 Aug 01; 79(15):9970-81. PubMed ID: 16014957
    [Abstract] [Full Text] [Related]

  • 13. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, Gonen M, Ebright MI, Culliford A, Gusani NJ, Fong Y.
    Cancer Gene Ther; 2006 Mar 01; 13(3):326-34. PubMed ID: 16138120
    [Abstract] [Full Text] [Related]

  • 14. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.
    Hellums EK, Markert JM, Parker JN, He B, Perbal B, Roizman B, Whitley RJ, Langford CP, Bharara S, Gillespie GY.
    Neuro Oncol; 2005 Jul 01; 7(3):213-24. PubMed ID: 16053696
    [Abstract] [Full Text] [Related]

  • 15. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
    Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS.
    Stem Cells; 2008 Mar 01; 26(3):831-41. PubMed ID: 18192232
    [Abstract] [Full Text] [Related]

  • 16. Assessment of 123I-FIAU imaging of herpes simplex viral gene expression in the treatment of glioma.
    Dempsey MF, Wyper D, Owens J, Pimlott S, Papanastassiou V, Patterson J, Hadley DM, Nicol A, Rampling R, Brown SM.
    Nucl Med Commun; 2006 Aug 01; 27(8):611-7. PubMed ID: 16829761
    [Abstract] [Full Text] [Related]

  • 17. Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells.
    Li S, Tokuyama T, Yamamoto J, Koide M, Yokota N, Namba H.
    Cancer Gene Ther; 2005 Jul 01; 12(7):600-7. PubMed ID: 15775995
    [Abstract] [Full Text] [Related]

  • 18. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
    Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1546-57. PubMed ID: 17077357
    [Abstract] [Full Text] [Related]

  • 19. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
    Conner J, Braidwood L, Brown SM.
    Gene Ther; 2008 Dec 01; 15(24):1579-92. PubMed ID: 18701918
    [Abstract] [Full Text] [Related]

  • 20. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.
    Geoerger B, Vassal G, Opolon P, Dirven CM, Morizet J, Laudani L, Grill J, Giaccone G, Vandertop WP, Gerritsen WR, van Beusechem VW.
    Cancer Res; 2004 Aug 15; 64(16):5753-9. PubMed ID: 15313916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.